<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1755">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784300</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-125-01</org_study_id>
    <secondary_id>1R44AG056166</secondary_id>
    <nct_id>NCT03784300</nct_id>
  </id_info>
  <brief_title>A Safety Study of PTI-125 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pain Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Cassava Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending&#xD;
      Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase I, single center, randomized, double-blind, placebo-controlled, single&#xD;
      ascending dose (SAD) study in healthy volunteers, 18 to 45 years of age. A total of&#xD;
      twenty-four (24) subjects were enrolled into the study in one of three dose cohorts. Each&#xD;
      cohort contained eight subjects; six subjects received PTI-125 and two received placebo.&#xD;
      Three doses of PTI-125 oral solution (50, 100, and 200 mg) or placebo solution were&#xD;
      administered to respective cohorts.&#xD;
&#xD;
      The study included a screening period (Day -28 to Day -1), an inpatient treatment period (Day&#xD;
      0 through Day 4), and a follow-up visit (Day 7). Subjects reported to the clinic on the day&#xD;
      before dosing and were randomized to receive either a single dose of orally administered&#xD;
      PTI-125 or placebo. Each dose was administered following an overnight fast of at least 10&#xD;
      hours.&#xD;
&#xD;
      For each dose level, dosing was staggered such that two subjects (one active and one placebo)&#xD;
      were dosed prior to the rest of the group. After a minimum of 24 hours and review of all&#xD;
      24-hour safety assessments (electrocardiogram [ECG], a brief physical examination, vital&#xD;
      signs, and laboratory assessments) an independent Data Safety Monitoring Board/Data&#xD;
      Monitoring Committee (DSMB/DMC) determined whether the remaining 6 subjects were to be dosed.&#xD;
&#xD;
      Pharmacokinetic blood samples were obtained prior to dosing and at specified intervals during&#xD;
      the study (0-72 hours post-dose). Blood draws for laboratory testing were performed prior to&#xD;
      dosing and at 24 hours post dose. After safety assessments of ECG, vital signs, and a brief&#xD;
      physical exam at 72 hours, subjects were discharged from the clinic and returned 7 days&#xD;
      post-dose for a final safety assessment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2017</start_date>
  <completion_date type="Actual">March 27, 2018</completion_date>
  <primary_completion_date type="Actual">October 9, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single center, randomized, double-blind, placebo controlled, SAD study of three escalating doses of PTI-125. A total of 24 healthy subjects enrolled in one of three dose cohorts. Each cohort will contain 8 subjects; six receive PTI-125 and two receive placebo. Three SAD does of PTI-125 oral solution (50, 100 or 200 mg) or placebo solution will be administered.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The peak drug concentration will be obtained directly from the data without interpolation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) (Tmax)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The time to peak drug concentration will be obtained directly from the data without interpolation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Last Quantifiable Plasma Concentration (Tlast)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Last Quantifiable Plasma Concentration (Clast)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination Rate Constant (λz)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The elimination rate constant (λz) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Termination Elimination Half-Life (T1/2)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The terminal elimination half-life (T1/2) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve to Infinity (AUCinf)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]).</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The percentage of AUCinf based on extrapolation (AUCextrap[%]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Clearance (Cl/F)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>The apparent oral clearance will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vz/F)</measure>
    <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
    <description>Vz/F, apparent volume of distribution will be calculated.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alzheimer Disease, Early Onset</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>50 mg PTI-125</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg PTI-125 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PTI-125</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg PTI-125 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg PTI-125</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg PTI-125 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mg PTI-125</intervention_name>
    <description>PTI-125 50 mg Oral Solution</description>
    <arm_group_label>50 mg PTI-125</arm_group_label>
    <arm_group_label>50 mg PTI-125 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 mg PTI-125</intervention_name>
    <description>PTI-125 100 mg Oral Solution</description>
    <arm_group_label>100 mg PTI-125</arm_group_label>
    <arm_group_label>100 mg PTI-125 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg PTI-125</intervention_name>
    <description>PTI-125 200 mg Oral Solution</description>
    <arm_group_label>200 mg PTI-125</arm_group_label>
    <arm_group_label>200 mg PTI-125 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects between 18 and 45 years of age, inclusive.&#xD;
&#xD;
          -  The subject has a body mass index (BMI) within 18-30 kg/m2 (inclusive).&#xD;
&#xD;
          -  The subject is in good health as determined by medical history and physical&#xD;
             examination and clinical laboratory parameters.&#xD;
&#xD;
          -  The subject is willing and able to speak, read, and understand English and provide&#xD;
             written informed consent.&#xD;
&#xD;
          -  The subject is a non-smoker for at least 12 months. If a former smoker, the reason for&#xD;
             stopping must be evaluated.&#xD;
&#xD;
          -  Females who are physically incapable of childbearing defined as postmenopausal, or&#xD;
             surgically sterile (hysterectomy, bilateral tubal ligation, bilateral oophorectomy or&#xD;
             an Essure procedure). Appropriate documentation (ex; medical record) of the surgical&#xD;
             sterilization procedure to be obtained and held within the subject's study file.&#xD;
&#xD;
          -  The subject must agree to comply with the drawing of blood samples for the PK&#xD;
             assessments.&#xD;
&#xD;
          -  The subject is willing and able to comply with all testing and requirements defined in&#xD;
             the protocol.&#xD;
&#xD;
          -  The subject is willing and able to remain at the study site unit for the duration of&#xD;
             the confinement period and return for the outpatient visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any relevant deviations from normal in physical examination,&#xD;
             electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the&#xD;
             investigator.&#xD;
&#xD;
          -  The subject has had a clinically significant illness within 30 days of Check-in.&#xD;
&#xD;
          -  The subject has a history of significant neurological, hepatic, renal, endocrine,&#xD;
             cardiovascular, gastrointestinal, pulmonary, or metabolic disease.&#xD;
&#xD;
          -  The subject has used any prescription medication within 14 days of dosing or overthe-&#xD;
             counter (OTC) medication within 48 h of dosing or intends to use any prescription&#xD;
             medication or OTC medication during the study that may interfere with the evaluation&#xD;
             of study medication.&#xD;
&#xD;
          -  The subject has used alcohol, caffeine or xanthine-containing products 48 h before&#xD;
             dosing or intends to use any of these products during the study.&#xD;
&#xD;
          -  The subject has used grapefruit, grapefruit juice, or grapefruit-containing products&#xD;
             days before dosing or intends to use any of these products during the study.&#xD;
&#xD;
          -  The subject has a history of substance abuse or a positive ethanol breath test, urine&#xD;
             cotinine, or urine drug screen at screening or at check-in. The subject has a positive&#xD;
             serum hepatitis B surface antigen or positive HCV antibody test at the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  The subject has a positive HIV test at the Screening Visit.&#xD;
&#xD;
          -  Female subject is pregnant or breastfeeding.&#xD;
&#xD;
          -  The subject has received an investigational drug within 30 days of Check-in.&#xD;
&#xD;
          -  The subject has donated or lost a significant volume of blood (&gt;450 mL) within 4 weeks&#xD;
             prior to the study.&#xD;
&#xD;
          -  The subject is unwilling to reside in the study unit for the duration of the study or&#xD;
             to cooperate fully with the investigator or site personnel.&#xD;
&#xD;
          -  The subject has an AST/ALT or total bilirubin greater than the ULN. One repeat test&#xD;
             will be allowed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George J Atiee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Worldwide Clinical Trials</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Worldwide Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <results_first_submitted>July 27, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2021</results_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03784300/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>50 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
        </group>
        <group group_id="P2">
          <title>50 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
        </group>
        <group group_id="P3">
          <title>100 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
        </group>
        <group group_id="P4">
          <title>100 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
        </group>
        <group group_id="P5">
          <title>200 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
        </group>
        <group group_id="P6">
          <title>200 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>50 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
        </group>
        <group group_id="B2">
          <title>50 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
        </group>
        <group group_id="B3">
          <title>100 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
        </group>
        <group group_id="B4">
          <title>100 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
        </group>
        <group group_id="B5">
          <title>200 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
        </group>
        <group group_id="B6">
          <title>200 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.2" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B2" value="31.8" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B3" value="35.3" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B4" value="31.8" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B5" value="35.8" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B6" value="31.8" lower_limit="18" upper_limit="45"/>
                    <measurement group_id="B7" value="35.3" lower_limit="18" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>The peak drug concentration will be obtained directly from the data without interpolation.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>The peak drug concentration will be obtained directly from the data without interpolation.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" spread="96.6"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="550" spread="146"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="1240" spread="276"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) (Tmax)</title>
        <description>The time to peak drug concentration will be obtained directly from the data without interpolation</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) (Tmax)</title>
          <description>The time to peak drug concentration will be obtained directly from the data without interpolation</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.69"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="1.08" spread="0.48"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="1.28" spread="0.57"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Last Quantifiable Plasma Concentration (Tlast)</title>
        <description>The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Last Quantifiable Plasma Concentration (Tlast)</title>
          <description>The time to the last quantifiable drug concentration will be obtained directly from the data without interpolation.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" spread="16.4"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="46.0" spread="4.6"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="50.00" spread="11.8"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Last Quantifiable Plasma Concentration (Clast)</title>
        <description>The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Last Quantifiable Plasma Concentration (Clast)</title>
          <description>The concentration of the last quantifiable drug will be obtained directly from the data without interpolation concentration</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.495"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="0.795" spread="0.294"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="0.806" spread="0.292"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Elimination Rate Constant (λz)</title>
        <description>The elimination rate constant (λz) will be calculated.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (λz)</title>
          <description>The elimination rate constant (λz) will be calculated.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>1/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.141" spread="0.0539"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="0.157" spread="0.0155"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="0.144" spread="0.0516"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Termination Elimination Half-Life (T1/2)</title>
        <description>The terminal elimination half-life (T1/2) will be calculated.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Termination Elimination Half-Life (T1/2)</title>
          <description>The terminal elimination half-life (T1/2) will be calculated.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="3.87"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="4.45" spread="0.39"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="5.93" spread="3.87"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC)</title>
        <description>The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC)</title>
          <description>The AUC from time zero to the time of the last quantifiable concentration (AUClast) will be calculated.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2040" spread="893"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="3130" spread="1150"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="8130" spread="1530"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve to Infinity (AUCinf)</title>
        <description>The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve to Infinity (AUCinf)</title>
          <description>The AUC from time zero extrapolated to infinity (AUCinf) will be calculate.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2180" spread="897"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="3260" spread="1150"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="8250" spread="1530"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]).</title>
        <description>The percentage of AUCinf based on extrapolation (AUCextrap[%]).</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Extrapolated of Area Under the Curve to Infinity (AUCextrap[%]).</title>
          <description>The percentage of AUCinf based on extrapolation (AUCextrap[%]).</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>percent extrapolated</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410" spread="0.187"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O3" value="0.151" spread="0.0366"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                    <measurement group_id="O5" value="0.144" spread="0.0156"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk values N/A for placebo subjects</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Oral Clearance (Cl/F)</title>
        <description>The apparent oral clearance will be calculated.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Oral Clearance (Cl/F)</title>
          <description>The apparent oral clearance will be calculated.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>(L/h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" spread="8.42"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk value not available as these are placebo patients</measurement>
                    <measurement group_id="O3" value="33.0" spread="8.16"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk value not available as these are placebo patients</measurement>
                    <measurement group_id="O5" value="24.9" spread="4.53"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk value not available as these are placebo patients</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vz/F)</title>
        <description>Vz/F, apparent volume of distribution will be calculated.</description>
        <time_frame>Blood samples will be drawn on Day 1 after dosing at 20, 40, and 60 minutes and at 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours.</time_frame>
        <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>50 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O2">
            <title>50 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
          </group>
          <group group_id="O3">
            <title>100 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O4">
            <title>100 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
          </group>
          <group group_id="O5">
            <title>200 mg PTI-125</title>
            <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
          <group group_id="O6">
            <title>200 mg PTI-125 Placebo</title>
            <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vz/F)</title>
          <description>Vz/F, apparent volume of distribution will be calculated.</description>
          <population>Separate dose cohorts of 6 active and 2 placebo received 50, 100, or 200 mg. A sentinel dose group of 1 active and 1 placebo preceded each full dose cohort.</population>
          <units>(L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199" spread="64.9"/>
                    <measurement group_id="O2" value="NA" spread="NA">Pk value not available as these are placebo patients</measurement>
                    <measurement group_id="O3" value="215" spread="64.8"/>
                    <measurement group_id="O4" value="NA" spread="NA">Pk value not available as these are placebo patients</measurement>
                    <measurement group_id="O5" value="214" spread="154"/>
                    <measurement group_id="O6" value="NA" spread="NA">Pk value not available as these are placebo patients</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>50 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 50 mg PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
        </group>
        <group group_id="E2">
          <title>50 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 50 mg Placebo PTI-125 in this cohort.&#xD;
50 mg PTI-125: PTI-125 50 mg Oral Solution</description>
        </group>
        <group group_id="E3">
          <title>100 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 100 mg PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
        </group>
        <group group_id="E4">
          <title>100 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 100 mg Placebo PTI-125 in this cohort.&#xD;
100 mg PTI-125: PTI-125 100 mg Oral Solution</description>
        </group>
        <group group_id="E5">
          <title>200 mg PTI-125</title>
          <description>Six (6) subjects will receive a single orally administered dose of 200 mg PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
        </group>
        <group group_id="E6">
          <title>200 mg PTI-125 Placebo</title>
          <description>Two (2) subjects will receive a single orally administered dose of 200 mg Placebo PTI-125 in this cohort.&#xD;
200 mg PTI-125: PTI-125 200 mg Oral Solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>medDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>transient musculoskeletal wall pain</sub_title>
                <description>One subject in the 200 mg group reported transient musculoskeletal wall pain</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>lightheadedness</sub_title>
                <description>lightheadedness upon standing was resported for a subject in the 100 mg group at 1 h post-dose</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <description>The same subject in the 200 mg group who reported transient musculoskeletal wall pain, also reported acne</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael R Marsman, PharmD</name_or_title>
      <organization>Cassava Sciences</organization>
      <phone>5125822173</phone>
      <email>mmarsman@cassavasciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

